Portal de Periódicos da CAPES

Efficacy and tolerance of policresulen in the treatment of the genitourinary syndrome of menopause

2019; MedCrave Group; Volume: 3; Issue: 3 Linguagem: Inglês

10.15406/ijfcm.2019.03.00145

2577-8269

Franklin José Espitia De La Hoz,

Menopause: Health Impacts and Treatments

Objective: To evaluate the efficacy and tolerance of policresulen in the treatment of genitourinary syndrome of menopause Materials and methods: Controlled clinical trial, randomized, masked "double-blind".321 women aged 40 or older, diagnosed with genitourinary syndrome of menopause, who had engaged in sexual activity in the last six weeks, and had visited a Level III private health care institution in Armenia, Quindío (Colombia), from February to December 2018 were included.Women under hormonal treatment and with absolute contraindications for the use of policresulen were excluded.Women were randomly assigned to two treatments: 117 received policresulen and 114 placebos (control group).Efficacy and tolerance were evaluated, as well as the adverse effects presented during the 12 weeks of follow-up.A nonstrict consecutive sampling was made. Results:The dose of policresulen was effective for symptom control, showing an efficacy of 76.92%, (n=90/117), versus 38.59%, (n=44/117) in the placebo group, with a statistically significant difference (p=0.003).Policresulen tolerance was adequate in 91.45% of women, compared to 92.98% of placebos, without statistically significant difference (p=0.375).The incidence of adverse effects was as follows: local burning sensation (4.27%), discharge of mucosal tissue fragments (2.56%) and vaginal candidiasis (1.7%) in the policresulen group, compared with, 5%, 1.75% and 1.75%, respectively, in the placebo group.There were fewer adverse effects in the placebo group, but there was no statistically significant difference between groups (89.74% vs. 92,1; p=0,27). Conclusion:The use of policresulen in women with genitourinary syndrome of menopause is effective for the management of the most frequent symptomatology.Although it is true that it is not the first therapeutic line of treatment, it should be considered in women for whom estrogen therapy is contraindicated or in those who do not wish to receive it.There was a low presence of adverse effects at the dose used, however, these were tolerable and did not require the interruption of the medication.